Junjun Yang's research while affiliated with Peking Union Medical College Hospital and other places

... However, as shown in our illustrated example, pooling information from several different studies could help to increase sample size and, consequently, the statistical power to detect significant additive interactions. Moreover, in scenarios where the outcome is common and a large effect size is expected, such as when evaluating progression-free survival for combined invasive therapies such as chemotherapy and surgery against cancer [21], a smaller sample size (e.g., ≈1000 to 5000 individuals) can provide sufficient statistical power. Lastly, it is also important to emphasize that even in studies with limited statistical power, estimating in an exploratory way can still yield valuable insights for guiding future research. ...

... In 57 individuals (81.4%), complete cytoreduction was performed. Adjuvant chemotherapy was found to be ineffective compared to those who did not receive it, however hormone therapy was not analyzed 16 . ...

... В мировой литературе описаны единичные наблюдения успешного органосохраняющего лечения [5][6][7][8][9]. Мы представляем редкое наблюдение комбинированного лечения ТОПЛ с сохранением фертильности пациентки. ...

... Thought the current case did not received immunotherapy, and there is no report of patients with GTN and intracardiac metastasis who experience PD-1 and PD-L1 inhibitor, immunotherapy in GTN has made great progress in recent years, with successful therapeutic outcomes in several clinical studies [26][27][28][29]. Previous researches have revealed that programmed cell death ligand (PD-L1) is highly expressed in GTN tumor tissue [30,31], and other immune targets TIM-3, LAG-3, and GAL-9 are also widely expressed in GTN [32]. The CAP-01 clinical trial confirmed the efficiency and safety of PD-1 inhibitor in patients with chemo-refractory and relapsed CTN, and showed a 55% of objective response rate [28]. ...

... Fertility-sparing surgical approaches and assisted reproductive technologies (ARTs), including ovarian transposition and cryopreservation of oocytes or embryos, are preferred strategies. Emerging techniques, such as antiapoptotic/cell-preserving agents and stem cell technologies, are advancing the field of fertility preservation 31 . ...

... However, surgery can still be valuable in certain cases. Previous studies 9 have shown that surgery should be performed in patients with pulmonary metastases who experience drug resistance and tumor recurrence. Additionally, research 10 has shown that resection can result in a complete remission rate of approximately 90% for stage III patients with drug resistance. ...

... BOT are associated with excellent prognosis with recurrence rates that can occur after 5-10 years, between 0 and 25% [67,68]. In stage I disease, FSS is well tolerated with 5-year DFS of 97.6%, similar to radical surgery. ...

... This is considered indicative of high-risk GTN chemotherapy. Additionally, for high-risk GTN, regimens such as FAEV, or combination of 5-FU plus Act-D can also be used [18]. ...

... In patient with brain metastasis, up to 20% of patients with choriocarcinomas, a multimodal strategy including radiotherapy, surgery, and chemotherapy must be considered including the addition of high-dose methotrexate and/or intrathecal methotrexate infusion. Among those patients, the 5-year overall survival rate has been shown to be notably lower around 69-80% [60][61][62][63]. Approximately 20-30% of high-risk patients will fail EMACO. ...

... In previous studies, Tian et al. [7] have demonstrated the value of APTw in differentiating stage IA endometrial cancer from endometrial polyps with a diagnostic efficacy of 0.850. In addition, several studies have shown [27][28][29][30] that APTw is valuable for differentiating benign and malignant endometrial disease, assessing Ki-67 expression, preoperative risk assessment, and evaluating microsatellite instability status. ...